Document is current
Any future updates will be listed below
-
Authors
Marques, Inês P.
Madeira, Maria H.
Messias, Ana L.
Martinho, António C.-V.
Santos, Torcato
Sousa, David C.
Figueira, João
Cunha-Vaz, José https://orcid.org/0000-0002-0947-9850
-
Funding
Funding for this research was provided by:
COMPETE Portugal2020
Fundo de Inovação, Tecnologia e Economia Circular (Programa Interface (FITEC/CIT/2018/2))
- License Information
-
More Information
Article History
Received: 27 May 2020
Accepted: 3 September 2020
First Online: 6 October 2020
Compliance with ethical standards
:
: IP.M., M.H.M., A.L.M., T.S. A.C.-V.M and DS. do not have financial disclosures. J.F.: member of Advisory board for Alimera, Allergan, Bayer, Boehringer, and Novartis; J.C.-V. reports grants from Carl Zeiss Meditec outside the submitted work and is consultant for Alimera Sciences, Allergan, Bayer, Gene Signal, Novartis, Pfizer, Precision Ocular Ltd., Roche, Sanofi-Aventis, Vifor Pharma, and Carl Zeiss Meditec.
: PROGRESS was approved by the Institutional Ethical Review Board and registered at ClinicalTrials.gov (#NCT03010397).
: Each participant signed a written informed consent before the beginning of the study, agreeing to participate in the study, after all procedures were explained.
